文献速递骨质疏松与代谢性骨病

他汀类药物使用对老年人骨质疏松性骨折风险的年龄和剂量依赖性效应

Age- and dose-dependent effect of statin use on the risk of osteoporotic fracture in older adults.
PubMed 文献 · Osteoporos Int · 2023-08-08

该研究基于韩国国民健康保险服务老年队列数据库,纳入365,656例无骨质疏松病史且自2004年1月1日起开始使用他汀的老年人,随访至2012年12月31日。随访6.27年间发生54,959例骨质疏松性骨折,他汀使用与主要骨质疏松性骨折风险降低相关(调整HR 0.77,95%CI 0.72-0.83,P<0.001),且效应呈年龄和累积剂量依赖性。

要点

  • 他汀使用与主要骨质疏松性骨折风险降低相关,调整HR为0.77(95%CI 0.72-0.83,P<0.001)。
  • 髋部骨折调整HR为0.49(95%CI 0.38-0.62,P<0.001),椎体骨折调整HR为0.70(95%CI 0.64-0.77,P<0.001)。
  • 累积剂量越高骨折风险越低,≥1,095 cDDD组调整HR为0.22(95%CI 0.15-0.33)。

核心结论

  • 他汀使用与一般老年人群骨质疏松性骨折风险显著降低相关。

研究设计与样本

  • 基于韩国国民健康保险服务老年队列数据库的观察性研究,纳入365,656例无既往骨质疏松病史且自2004年1月1日起开始使用他汀的老年人,随访至2012年12月31日。
  • 采用逆概率治疗加权法的加权Cox比例风险模型计算主要骨质疏松性骨折的风险比(HR)。

主要发现

  • 随访6.27年间共发生54,959例骨质疏松性骨折,其中69.5%为椎体骨折。
  • 与未使用者相比,他汀使用与主要骨质疏松性骨折风险降低相关,调整HR为0.77(95%CI 0.72-0.83,P<0.001)。
  • 髋部骨折调整HR为0.49(95%CI 0.38-0.62,P<0.001),椎体骨折调整HR为0.70(95%CI 0.64-0.77,P<0.001)。
  • 按性别分析时风险降低模式大致相当;80岁及以上开始使用他汀的患者相对未使用者大多数结局的风险降低幅度最大。
  • 累积剂量越高骨折风险越低:30-364 cDDD调整HR为0.97(95%CI 0.91-1.02),365-1,094 cDDD为0.45(95%CI 0.40-0.51),≥1,095 cDDD为0.22(95%CI 0.15-0.33)。

关键数值与推荐

  • 主要骨质疏松性骨折:调整HR 0.77(95%CI 0.72-0.83,P<0.001)。
  • 髋部骨折:调整HR 0.49(95%CI 0.38-0.62,P<0.001)。
  • 椎体骨折:调整HR 0.70(95%CI 0.64-0.77,P<0.001)。
  • 累积剂量30-364 cDDD:调整HR 0.97(95%CI 0.91-1.02);365-1,094 cDDD:调整HR 0.45(95%CI 0.40-0.51);≥1,095 cDDD:调整HR 0.22(95%CI 0.15-0.33)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Previous studies have revealed the protective effects of statins on bone but the association of statins use with osteoporosis-related measurement has shown controversial results. In this study, we found an age, dose andduration-dependent osteoprotective effect of statins in general older population. PURPOSE: Previous studies have revealed the protective effects of statins on bone but the association of statins use with osteoporotic fractures has shown controversial results. METHODS: In this study with Korean National Health Insurance Service-Senior cohort database, a total of 365,656 elderly without previous history of osteoporosis and who were started on statin since January 1 2004 were included and observed until December 31 2012. Hazard rations (HR) for major osteoporotic fractures were calculated using the weighted Cox proportional hazards model with inverse-probability of treatment weighting method. RESULTS: During 6.27 years of follow-up period, 54,959 osteoporotic fractures occurred and the majority of fractures (69.5%) were vertebral fractures. Compared with non-users, statin use was associated with a decreased risk of all outcomes with adjusted HR (95% CI) of 0.77 (0.72-0.83; P < 0.001) for major osteoporotic fractures, 0.49 (0.38-0.62; P < 0.001) for hip fractures, and 0.70 (0.64-0.77; P < 0.001) for vertebral fractures. When outcomes were examined separately by sex, the results were broadly comparable in terms of patterns of risk reduction by statin use. The patients with statin initiated at age ≥ 80 years had the highest risk reduction for most outcomes relative to non-users. Higher cumulative dose of statin was negatively associated with the osteoporotic fracture risk; 0.97 (0.91-1.02) for 30-364 cumulative daily defined dose (cDDD), 0.45 (0.40-0.51) for 365-1,094 cDDD, and 0.22 (0.15-0.33) for ≥ 1,095 cDDD. CONCLUSIONS: Our results showed that statin use was associated with significant reduction in the risk of osteoporotic fractures in general older population.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Seo DH, Jeong Y, Cho Y, et al. Age- and dose-dependent effect of statin use on the risk of osteoporotic fracture in older adults. Osteoporos Int. 2023. PMID: 37552294. doi:10.1007/s00198-023-06879-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。